MedMatrix Rx
Daily 340B Morning Briefing
Johnson & Johnson’s new requirement for 340B covered entities to submit claims data for drug discounts is a significant development. The American Hospital Association is pushing for a permanent ban on rebate models in the 340B program, citing potential burdens. Meanwhile, a federal rebate pilot for 340B pricing is set to begin in 2027. These shifts reflect ongoing adjustments in the 340B program, with implications for hospitals and manufacturers alike.
EXECUTIVE SUMMARY
01
Johnson & Johnson mandates claims data for 340B pricing.
Starting September 15, 340B covered entities must submit claims-level data to Johnson & Johnson to maintain 340B pricing.
Starting September 15, 340B covered entities must submit claims-level data to Johnson & Johnson to maintain 340B pricing.
Source: Becker’s Hospital Review
02
AHA calls for permanent ban on 340B rebate models.
The American Hospital Association urges Congress to permanently prohibit rebate models in the 340B program, citing potential burdens.
The American Hospital Association urges Congress to permanently prohibit rebate models in the 340B program, citing potential burdens.
Source: Becker’s Hospital Review
03
Federal rebate pilot for 340B pricing to start in 2027.
A limited federal rebate pilot will allow qualifying manufacturers to provide 340B pricing through rebates starting January 1, 2027.
A limited federal rebate pilot will allow qualifying manufacturers to provide 340B pricing through rebates starting January 1, 2027.
Source: Becker’s Hospital Review
04
340B hospitals report less charity care than non-340B hospitals.
A report finds 340B hospitals spend a smaller share of their budgets on charity care compared to non-340B hospitals.
A report finds 340B hospitals spend a smaller share of their budgets on charity care compared to non-340B hospitals.
Source: Becker’s Hospital Review
05
States enact laws to protect 340B contract pharmacy arrangements.
Several states have passed laws requiring manufacturers to honor 340B pricing at contract pharmacies, facing legal challenges.
Several states have passed laws requiring manufacturers to honor 340B pricing at contract pharmacies, facing legal challenges.
Source: AHA
06
340B margins squeezed by new federal policies and lower list prices.
340B covered entities are experiencing margin reductions due to lower list prices and new federal policies, impacting health centers more.
340B covered entities are experiencing margin reductions due to lower list prices and new federal policies, impacting health centers more.
Source: Drug Channels
07
ASHP advocates for 340B program protections on Capitol Hill.
ASHP members are lobbying for expanded Medicare coverage and 340B program protections, including pharmacy residency training.
ASHP members are lobbying for expanded Medicare coverage and 340B program protections, including pharmacy residency training.
Source: Becker’s Hospital Review
08
NASP comments on CMS’ proposed 340B payment changes.
NASP submitted comments on CMS’ proposed changes to Medicare reimbursement for 340B-acquired drugs, focusing on operational impacts.
NASP submitted comments on CMS’ proposed changes to Medicare reimbursement for 340B-acquired drugs, focusing on operational impacts.
Source: NASP
09
Missouri court denies rehearing in contract pharmacy case.
A court denied petitions for rehearing in a case challenging Missouri’s state law on 340B contract pharmacy arrangements.
A court denied petitions for rehearing in a case challenging Missouri’s state law on 340B contract pharmacy arrangements.
Source: NewsBreak
10
340B hospitals face criticism over charity care spending.
Critics argue 340B hospitals provide less charity care despite program benefits, sparking debate over the program’s impact.
Critics argue 340B hospitals provide less charity care despite program benefits, sparking debate over the program’s impact.
Source: Medical Daily
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The shift to a rebate model for 340B pricing could significantly impact hospital cash flow and staffing. Hospitals currently benefit from upfront discounts when purchasing drugs. The change to a rebate system means hospitals will need to manage cash flow differently, potentially affecting their financial stability. This could lead to adjustments in staffing and operational decisions as hospitals adapt to the new model. The rebate model aims to improve transparency and prevent duplicate discounts, which could affect program integrity but also increase administrative burdens for hospitals.
Emerging risks.
- Hospitals may face cash flow challenges with the shift to a rebate model for 340B pricing.
- Increased administrative burdens from new reporting requirements could strain hospital resources.
- Legal challenges to state laws protecting 340B arrangements could disrupt contract pharmacy operations.
- Reduced 340B margins due to lower list prices may impact hospital financial stability.
Emerging opportunities.
- Hospitals can improve transparency and program integrity by complying with new claims data requirements.
- The federal rebate pilot provides a chance to improve claims-level transparency and prevent duplicate discounts.
- Engaging with policymakers could shape future 340B program reforms to benefit hospitals.
- Hospitals can use state laws protecting 340B arrangements to maintain patient access.
Key actions for providers.
- Hospitals should prepare for the transition to a rebate model by reviewing cash flow management strategies.
- Covered entities must ensure timely submission of claims data to maintain 340B pricing.
- Engage with legal counsel to address challenges to state laws protecting 340B arrangements.
- Monitor federal policy developments to anticipate and adapt to changes in 340B program requirements.
TOP STORIES
Johnson & Johnson mandates claims data for 340B pricing.
Becker’s Hospital Review · September 11, 2026
- Starting September 15, 340B covered entities must submit claims-level data to maintain pricing.
- Noncompliance leads to pricing suspension, restored upon data submission within 10 business days.
AHA calls for permanent ban on 340B rebate models.
Becker’s Hospital Review · September 25, 2026
- AHA urges Congress to prohibit rebate models in the 340B program permanently.
- The SECURE 340B Act, introduced in July, combines hospital protections with new requirements.
Federal rebate pilot for 340B pricing to start in 2027.
Becker’s Hospital Review · September 28, 2026
- A federal rebate pilot will allow 340B pricing through rebates starting January 1, 2027.
- The pilot aims to improve claims-level transparency and prevent duplicate discounts.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
States enact laws to protect 340B contract pharmacy arrangements.
AHA · September 2, 2026
- Several states require manufacturers to honor 340B pricing at contract pharmacies.
- Manufacturers have challenged these state laws in courts nationwide.
ASHP advocates for 340B program protections on Capitol Hill.
Becker’s Hospital Review · September 16, 2026
- ASHP members seek expanded Medicare coverage for pharmacist-provided care.
- They advocate for protections for the 340B Drug Pricing Program.
NASP comments on CMS’ proposed 340B payment changes.
NASP · September 1, 2026
- NASP submitted comments on proposed changes to Medicare reimbursement for 340B drugs.
- The comments focus on operational impacts and preserving patient access.
340B PROGRAM DEVELOPMENTS
340B hospitals report less charity care than non-340B hospitals.
Becker’s Hospital Review · September 28, 2026
- 340B hospitals spent 2.16% of operating expenses on charity care, less than non-340B hospitals.
- The report identifies a transparency gap in how 340B savings are used.
340B margins squeezed by new federal policies and lower list prices.
Drug Channels · September 29, 2026
- 340B covered entities face reduced margins due to lower list prices and federal policies.
- Health centers are more affected than hospitals due to Part D drug share.
STATE DEVELOPMENTS
Missouri court denies rehearing in contract pharmacy case.
NewsBreak · September 24, 2026
- A court denied petitions for rehearing in a case challenging Missouri’s 340B contract pharmacy law.
- The decision is part of ongoing legal challenges to state 340B laws.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
| E.D. Mich. | Henry Ford Hospital v. CVS Health Corporation — Reply to Response to Motion. Case filed July 16, 2026. [source] | September 23, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Memorandum in support re Motion to Dismiss. Case filed July 2, 2026. [source] | September 23, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Objection to 5 motion for Preliminary Injunction Defendant’s Opposition to Plaintiff’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | September 17, 2026 |
| 8th Cir. | Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway — Judge order: The petition for rehearing en banc is denied. The petition for panel rehearing is also denied. Case filed March 28, 2025. [source] | September 16, 2026 |
| 8th Cir. | AbbVie, Inc. v. Marty Jackley — Motion to hold briefing schedule in abeyance. Case filed August 11, 2026. [source] | September 15, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Johnson & Johnson | Requires 340B covered entities to submit claims data for drug discounts. [source] | September 11, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
I conducted a web search for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.
Is This Drug Pricing Program Actually Making US Healthcare Affordability Crisis, Hospital Consolidation Worse?
Center for Healthcare Affordability · July 12, 2026
- Main theme: Debate over 340B program’s impact on healthcare affordability and hospital consolidation
- Stakeholder sentiment: Analysts warn that the 340B program may contribute to hospital consolidation and worsen affordability issues.
- Potential implications: Potential exacerbation of healthcare affordability challenges and increased hospital consolidation.
- Credibility: The Center for Healthcare Affordability is an organization focused on healthcare policy analysis.
WHAT TO WATCH NEXT
- Implementation of J&J’s claims data requirement for 340B pricing on September 15. [source]
- Potential Congressional action on the SECURE 340B Act following AHA’s comments. [source]
- Federal rebate pilot for 340B pricing starting January 1, 2027. [source]
- Legal developments in state 340B contract pharmacy law challenges. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.